Eli Lilly On Thursday, he reported income and profits of the first quarter that increased estimates as the demand for their weight loss and diabetes medications shot, but reduced their earning guide throughout the year due to charges related to a recent agreement on cancer treatment.
The pharmaceutical giant now hopes that its adjusted tax earnings 2025 will be between $ 20.78 and $ 22.28 per share, below an earlier guide from $ 22.50 to $ 24 per share. Eli Lilly said the review reflects a charge of $ 1.57 billion registered in the first quarter, which is mainly related to the acquisition of a certain medication against oral cancer of Scorpion Therapeutics.
The company maintained its 2025 Fiscal Sales Guide from $ 58 billion to $ 61 billion. Eli Lilly said the guide reflects the existing tariffs of President Donald Trump as of May 1, but does not include his planned levies on imported pharmaceutical products to the United States.
In an interview with CNBC, the CEO of Eli Lilly, Dave Ricks, said the company and other drug manufacturers are already announcing investments in the manufacture of the United States, which is one of the established objectives of the Trump administration tariffs.
“I think that in reality the threat of tariffs is already bringing critical supply chains to important industries, chips and pharmacists,” Ricks said. “We also need to promulgate [tariffs?] I'm not so sure. “
He added that Eli Lilly wants to see permanently lower tax rates in the United States, particularly 15% for national production. Ricks said the lowest taxes promoted many medicines manufacturers to manufacture in “low -tax islands such as Ireland Singapore and Switzerland, and that can return if there is an economic incentive.”
Eli Lilly's successful treatment of diabetes, Mounjaro exceeded expectations for the first quarter, raising $ 3.84 billion in revenues. That is a huge 113% since the same period a year ago.
The weight of weight loss of the Zepbound company also exceeded the estimates, reserving $ 2.31 billion in sales for the quarter. That more than quadrupled the $ 517.4 million that the treatment brought a year ago, when it had just entered the US market.
Analysts expected Mounjaro and Zepbound to generate $ 3.81 billion and $ 2.28 billion in sales, respectively, according to Streetacount estimates.
Eli Lilly's shares fell more than 9% on Thursday. That came later CVS health Thursday said that its pharmacy benefits manager would Novo Nordisk's Fill the preferred medication to lose weight in its main forms instead of Zepbound.
This is what Eli Lilly reported for the first quarter compared to what Wall Street expected, based on a LSEG analysts survey:
- Profit per action: $ 3.34 adjusted compared to $ 3.0 expected
- Revenue: $ 12.73 billion compared to $ 12.67 billion expected
The company registered income from the first quarter of $ 12.73 billion, 45% more than the same period of the previous year.
Sales in the United States increased 49% to $ 8.49 billion. Eli Lilly said it was driven by a 57% increase in volume, or the number of recipes or units sold, for Zepbound and Mounjaro. That was partially compensated by the lowest prices of medicines, the company said.
The pharmaceutical giant reserved a net income of $ 2.76 billion, or $ 3.06 per share, for the first quarter. That is compared to the net income of $ 2.24 billion, or $ 2.48 shares, a year earlier.
Excluding unique articles associated with the value of intangible assets and other adjustments, Eli Lilly registered earnings of $ 3.34 per share for the first quarter.
The demand in the US has still exceeded the offer of Zepbound and Mounjaro during the last year. Both called Incretina treatments imitate certain intestinal hormones to reduce a person's appetite and regulate their blood sugar.
The popularity of these injectable medications has forced both Eli Lilly and their rival Novo Nordisk to invest billions to increase the manufacturing capacity for their treatments.
The efforts seem to be paying off: the Food and Drug Administration in December reaffirmed its decision to declare the shortage of the US Tirzepaturo, the active ingredient in Zepbound and Mounjaro, on. This decision effectively forbids many pharmacies composed of marketing and sale of cheaper and unveiled versions of Tirzepatide.
